Skip to main content

Table 2 Causal effect estimates on diabetes via univariable Mendelian randomization

From: Leveraging IgG N-glycosylation to infer the causality between T2D and hypertension

Exposures

SNP (N)

OR (95%CI) (P value)

MR‒Egger (P value)

Weighted median method (P value)

MR‒Egger intercept (P value)

Hypertension

6

1.391 (1.081–1.790) (0.010)

2.018 (0.879–4.637) (0.098)

1.132 (0.928–1.381) (0.222)

− 0.350 (0.342)

GP1

134

1.074 (0.952–1.213) (0.247)

1.262 (0.985–1.618) (0.066)

1.112 (0.943–1.311) (0.206)

− 0.122 (0.204)

GP2

37

1.435 (1.190–1.731) (1.550 × 10–4)

1.567 (1.042–2.356) (0.031)

1.610 (1.174–2.207) (0.003)

− 0.057 (0.635)

GP3

35

1.169 (0.932–1.466) (0.177)

1.618 (1.023–2.557) (0.039)

1.509 (1.072–2.124) (0.018)

− 0.200 (0.142)

GP4

29

1.219 (0.937–1.586) (0.140)

1.043 (0.584–0.1863) (0.887)

1.271 (0.848–1.903) (0.246)

0.100 (0.518)

GP5

62

0.819 (0.681–0.984) (0.033)

1.394 (0.960–2.024) (0.081)

0.936 (0715–1.227) (0.634)

− 0.317 (0.008)

GP6

24

1.498 (1.515–1.950) (0.003)

2.633 (1.506–4.605) (0.001)

1.740 (1.115–2.716) (0.015)

− 0.285 (0.056)

GP7

27

0.892 (0.655–1.214) (0.466)

1.590 (0.921–2.744) (0.096)

0.935 (0.629–1.392) (0.742)

0.282 (0.060)

GP8

15

0.787 (0.546–1.133) (0.197)

0.748 (0.285–1.964) (0.556)

0.808 (0.480–1.359) (0.422)

0.008 (0.965)

GP9

15

1.069 (0.618–1.848) (0.811)

1.546 (0.543–4.403) (0.415)

0.917 (0.548–1.536) (0.743)

− 0.124 (0.507)

GP10

23

0.743 (0.526–1.050) (0.092)

1.257 (0.637–2.480) (0.510)

0.704 (0.455–1.091) (0.117)

− 0.256 (0.154)

GP11

17

0.936 (0.676–1.298) (0.693)

1.015 (0.476–2.165) (0.970)

0.944 (0.571–1.561) (0.823)

− 0.035 (0.828)

GP12

41

0.851 (0.659–1.099) (0.216)

1.216 (0.776–1.904) (0.393)

0.996 (0.711–1.395) (0.980)

− 0.184 (0.127)

GP13

48

0.916 (0.725–1.157) (0.462)

1.462 (0.975–2.193) (0.066)

1.010 (0.746–1.367) (0.948)

0.230 (0.030)

GP14

18

0.686 (0.424–1.110) (0.125)

0.812 (0.273–2.413) (0.707)

0.678 (0.369–1.246) (0.211)

− 0.064 (0.767)

GP15

17

0.560 (0.384–0.816) (0.003)

1.313 (0.436–3.953) (0.628)

0.602 (0.357–1.016) (0.057)

− 0.349 (0.153)

GP16

25

1.124 (0.860–1.468) (0.394)

1.138 (0.530–2.447) (0.740)

1.148 (0.777–1.697) (0.488)

− 0.007 (0.962)

GP17

53

0.889 (0.727–1.087) (0.251)

1.517 (1.044–2.204) (0.029)

1.014 (0.754–1.363) (0.927)

− 0.291 (0.011)

GP18

12

1.095 (0.634–1.892) (0.745)

1.496 (0.464–4.818) (1.496)

1.423 (0.757–2.674) (0.273)

− 0.156 (0.551)

GP19

22

1.286(0.984–1.681) (0.066)

1.303 (0.717–2.368) (0.385)

1.405 (0.931–2.122) (0.105)

− 0.017 (0.901)

GP20

62

0.857 (0.719–1.022) (0.086)

0.964 (0.617–1.504) (0.870)

0.891 (0.691–1.149) (0.374)

− 0.057 (0.731)

GP21

34

0.937 (0.725–1.212) (0.621)

1.204 (0.721–2.011) (0.478)

0.988 (0.692–1.411) (0.948)

− 0.202 (0.153)

GP22

219

1.178 (1.176–1.290) (4.097 × 10–4)

1.662 (1.270–2.174) (2.134 × 10–4)

1.253 (1.104–1.422) (4.948 × 10–4)

0.342 (0.013)

GP23

19

1.042 (0.704–1.542) (0.837)

0.921 (0.427–1.984) (0.833)

1.074 (0.683–1.689) (0.756)

0.084 (0.623)

GP24

21

1.925 (1.369–2.706) (1.661 × 10–4)

1.532 (0.539–4.354) (0.424)

2.182 (1.361–3.498) (0.001)

0.090 (0.650)

  1. The results in bold indicate that the P value is less than 0.05
  2. CI: confidence intervals; GP: glycan peak; OR: odds ratio; SE: standard error; SNP: single nucleotide polymorphism